First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Shrividya Iyer, Arlene Reisman, Keith D. Wilner, Jennifer Tursi, Fiona Blackhall

New England Journal of Medicine, 2014

Peter MacCallum Cancer Centre, Chinese University of Hong Kong, Seoul National University Hospital, Guangzhou Medical University, Cancer Institute (WIA), Guangzhou Medical University Cancer Hospital, Kindai University, Florida Hospital Cancer Institute, Vall d'Hebron Institute of Oncology, Hebron University, Ospedale di Livorno, Pfizer (Italy), Pfizer (United States), University of Manchester

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

3189

Citations

View on Google Scholar

First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back